$1.12
2.61% day before yesterday
Nasdaq, Dec 27, 09:49 pm CET
ISIN
US31447E1055
Symbol
FEMY

Femasys Inc Stock price

$1.13
+0.09 8.65% 1M
-0.02 1.74% 6M
+0.16 15.90% YTD
+0.18 18.95% 1Y
-2.79 71.17% 3Y
-10.87 90.58% 5Y
-10.87 90.58% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.02 1.74%
ISIN
US31447E1055
Symbol
FEMY
Sector

Key metrics

Market capitalization $25.88m
Enterprise Value $25.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 20.25
P/S ratio (TTM) P/S ratio 20.54
P/B ratio (TTM) P/B ratio 4.21
Revenue growth (TTM) Revenue growth 15.33%
Revenue (TTM) Revenue $1.26m
EBIT (operating result TTM) EBIT $-17.51m
Free Cash Flow (TTM) Free Cash Flow $-18.11m
Cash position $7.61m
EPS (TTM) EPS $-0.82
P/E forward negative
P/S forward 9.46
EV/Sales forward 9.32
Short interest 3.01%
Show more

Is Femasys Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Femasys Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Femasys Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Femasys Inc forecast:

Buy
100%

Financial data from Femasys Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.26 1.26
16% 16%
100%
- Direct Costs 1.33 1.33
5% 5%
106%
-0.07 -0.07
59% 59%
-6%
- Selling and Administrative Expenses 8.43 8.43
51% 51%
669%
- Research and Development Expense 8.12 8.12
27% 27%
644%
-17 -17
36% 36%
-1,319%
- Depreciation and Amortization 0.90 0.90
2% 2%
71%
EBIT (Operating Income) EBIT -18 -18
34% 34%
-1,390%
Net Profit -18 -18
42% 42%
-1,437%

In millions USD.

Don't miss a Thing! We will send you all news about Femasys Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Femasys Inc Stock News

Neutral
GlobeNewsWire
about one month ago
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients
Neutral
GlobeNewsWire
about 2 months ago
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe
Neutral
GlobeNewsWire
about 2 months ago
FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control
More Femasys Inc News

Company Profile

Femasys, Inc. operates as a medical device company that focuses on women's healthcare. Its products include FemVue Saline-Air Device, which creates and delivers an alternating pattern of saline and air as a continuous stream, and enables physicians to assess their patients fallopian tubes, and FemChec Pressure Management Device, which limits the maximum applied pressure while performing hysterosalpingogram. The firm offers FemCerv, an endocervical curettage device to collect a non-contaminated tissue sample for cervical cancer screening. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

Head office United States
CEO Kathy Lee-Sepsick
Employees 32
Founded 2004
Website www.femasys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today